SPY315.31-0.88 -0.28%
DIA259.12-1.60 -0.61%
IXIC10,537.46+44.96 0.43%

Argus Research Maintains Buy on GlaxoSmithKline, Raises Price Target to $50

Argus Research maintains GlaxoSmithKline (NYSE:GSK) with a Buy and raises the price target from $47 to $50.

Benzinga · -

Argus Research maintains GlaxoSmithKline (NYSE:GSK) with a Buy and raises the price target from $47 to $50.